About Carbylan
Carbylan is a company based in Palo Alto (United States) founded in 2004.. Carbylan has raised $42.9 million across 6 funding rounds from investors including Alta Partners, InterWest and Vivo Capital. The company has 7 employees as of December 31, 2022. Carbylan operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Palo Alto, United States
- Employees 7 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kalvista Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$42.9 M (USD)
in 6 rounds
-
Latest Funding Round
$4 M (USD), Series C
Mar 05, 2015
-
Investors
Alta Partners
& 2 more
-
Employee Count
7
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Carbylan
Carbylan is a publicly listed company on the NASDAQ with ticker symbol KALV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Sales and Marketing
9 people
Operations Team
5 people
Finance and Accounting
5 people
Software Development Team
5 people
Senior Team
4 people
Human Resources and Administration
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of Carbylan
Carbylan has successfully raised a total of $42.9M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $4 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series C — $4.0M
-
First Round
First Round
(22 Dec 2005)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2015 | Amount | Series C - Carbylan | Valuation |
investors |
|
| Oct, 2014 | Amount | Series C - Carbylan | Valuation |
investors |
|
| Jan, 2013 | Amount | Series C - Carbylan | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Carbylan
Carbylan has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Alta Partners, InterWest and Vivo Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare companies
|
Founded Year | Domain | Location | |
|
Early-stage investing in IT and healthcare ventures.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Carbylan
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Carbylan
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Carbylan Comparisons
Competitors of Carbylan
Carbylan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Carbylan
When was Carbylan founded?
Carbylan was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Where is Carbylan located?
Carbylan is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Is Carbylan a funded company?
Carbylan is a funded company, having raised a total of $42.9M across 6 funding rounds to date. The company's 1st funding round was a Series C of $6M, raised on Dec 22, 2005.
How many employees does Carbylan have?
As of Dec 31, 2022, the latest employee count at Carbylan is 7.
What does Carbylan do?
Carbylan develops therapeutics using polymers of hyaluronic acid. Its proprietary technology enables the crosslinking of hyaluronic acid to form hydrogels. Its lead candidate Hydros-TA is a low dose steroid - hydrogel formulation for pain management with symptomatic osteoarthritis (Phase 3). In Apr 2016, Carbylan pulls pain drug Phase 3 trial and puts itself up for sale. As of Nov 2016, Carbylan Therapeutics was acquired by KalVista Pharmaceuticals in a reverse merger transaction.
Who are the top competitors of Carbylan?
Carbylan's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Is Carbylan publicly traded?
Yes, Carbylan is publicly traded on NASDAQ under the ticker symbol KALV.
Who are Carbylan's investors?
Carbylan has 3 investors. Key investors include Alta Partners, InterWest, and Vivo Capital.
What is Carbylan's ticker symbol?
The ticker symbol of Carbylan is KALV on NASDAQ.